Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
|
|
Arcadia Biosciences, Inc. (RKDA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Arcadia Biosciences Announces Second-Quarter and First-Half 2023 Financial Results and Business Highlights • GoodWheatTMexpands into breakfast category with the launch of better-for-you pancake and waffle mixes • Exiting Body Care to reduce OpEx, focus on Food & Beverage • Exploring strategic opportunities to drive shareholder value DAVIS, Calif. – Arcadia Biosciences, Inc.® , a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the second quarter and first half of 2023. “Arcadia continues to make progress executing Project Greenfield, our three-year strategic plan to unlock the company’s potential and provide a path to profitability,” said Stan Jacot, president and CEO. &#x...",
"Arcadia Biosciences, Inc. Consolidated Balance Sheets Assets Current assets: Cash and cash equivalents $ 13,484 $ 20,644 Short-term investments 5,023 — Accounts receivable and other receivables, net of allowance for doubtful accounts of $1 and $3 as of June 30, 2023 and December 31, 2022, respectively 630 1,287 Inventories, net — current 3,164 2,571 Assets held for sale 87 87 Prepaid expenses and other current assets 951 809 Total current assets 23,339 25,398 Property and equipment, net 560 704 Right of use asset 1,384 1,848 Inventories, net — noncurrent 1,297 767 Intangible assets, net 40 40 Other noncurrent assets 178 165 Total assets $ 26,798 $ 28,922 Liabilities and stockholders’ equity Current liabilities: Accounts payable and accrued expenses $ 2,783 $ 2,881 Amounts due to related p..." |
|
| 08/07/2023 |
4
| Schaefer Thomas J. (CFO) has filed a Form 4 on Arcadia Biosciences, Inc.|
Txns:
| Bought 649 shares
@ $3.67, valued at
$2.4k
|
|
| 07/20/2023 |
8-K
| Quarterly results |
| 06/16/2023 |
4
| Carosella Deborah D (Director) has filed a Form 4 on Arcadia Biosciences, Inc.|
Txns:
| Granted 937 options to buy
@ $4.8, valued at
$4.5k
|
|
| 06/16/2023 |
4
| Yoder Amy (Director) has filed a Form 4 on Arcadia Biosciences, Inc.|
Txns:
| Granted 937 options to buy
@ $4.8, valued at
$4.5k
|
|
| 06/16/2023 |
4
| Bolles Albert D. (Director) has filed a Form 4 on Arcadia Biosciences, Inc.|
Txns:
| Granted 937 options to buy
@ $4.8, valued at
$4.5k
|
|
| 06/16/2023 |
4
| WALLER GREGORY D (Director) has filed a Form 4 on Arcadia Biosciences, Inc.|
Txns:
| Granted 937 options to buy
@ $4.8, valued at
$4.5k
|
|
| 06/16/2023 |
4
| Murray Lilian Shackelford (Director) has filed a Form 4 on Arcadia Biosciences, Inc.|
Txns:
| Granted 937 options to buy
@ $4.8, valued at
$4.5k
|
|
| 06/16/2023 |
4
| Comcowich Kevin (Director) has filed a Form 4 on Arcadia Biosciences, Inc.|
Txns:
| Granted 2,186 options to buy
@ $4.8, valued at
$10.5k
|
|
| 06/12/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/30/2023 |
4
| Jacot Stanley Jr (CEO) has filed a Form 4 on Arcadia Biosciences, Inc.|
Txns:
| Bought 5,000 shares
@ $4.31, valued at
$21.6k
|
|
| 05/25/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"Arcadia Biosciences Announces First Quarter 2023 Financial Results from Operations and Business Highlights – Significant improvement in gross profit dollars compared to last year – – GoodWheatTM pasta named “Best New Product” by Retail Dietitians Business Alliance – DAVIS, Calif. – Arcadia Biosciences, Inc.® , a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the first quarter of 2023. “We continue to focus on growing high quality revenue streams, as we closely manage resources,” said Stan Jacot, president and CEO. “And the impact of this focus is clearly seen in our Q1 results, with notable improvements in gross profit dollars and operating expenses compared to last year...",
"Arcadia Biosciences, Inc. Consolidated Statements of Operations and Comprehensive Loss Three Months Ended March 31, 2023 2022 Revenues: Product $ 1,509 $ 3,170 Royalty — 50 Total revenues 1,509 3,220 Operating expenses : Cost of revenues 825 3,458 Research and development 359 395 Change in fair value of contingent consideration — Gain on sale of property and equipment Selling, general and administrative 4,392 4,349 Total operating expenses 5,557 7,843 Loss from operations # # # 1" |
|
| 04/28/2023 |
4
| PITLIK LAURA (Chief Marketing Officer) has filed a Form 4 on Arcadia Biosciences, Inc.|
Txns:
| Granted 1,500 options to buy
@ $7.55, valued at
$11.3k
|
|
| 04/28/2023 |
4
| Jacot Stanley Jr (CEO) has filed a Form 4 on Arcadia Biosciences, Inc.|
Txns:
| Granted 1,500 options to buy
@ $7.55, valued at
$11.3k
|
|
| 04/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/25/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/25/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/18/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/13/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 04/03/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 02/28/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...|
Docs:
|
"CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ARCADIA BIOSCIENCES, INC. Arcadia Biosciences, Inc., a corporation organized under and existing under the laws of the State of Delaware , certifies that: FIRST: The name of the Corporation is Arcadia Biosciences, Inc. SECOND: The Board of Directors of the Corporation, acting in accordance with the provisions of Sections 141 and 242 of the Delaware General Corporation Law, duly approved and adopted resolutions to amend Article IV of the Amended and Restated Certificate of Incorporation of the Corporation, which is hereby amended to read in its entirety as follows: “ARTICLE IV A. Classes of Stock. The Corporation is authorized to issue two classes of stock to be designated, respectively, “Commo..." |
|
| 02/22/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 02/14/2023 |
SC 13G
| ARMISTICE CAPITAL, LLC reports a 10% stake in Arcadia Biosciences, Inc. |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/20/2023 |
SC 13D/A
| Moral Compass Corp reports a 4.6% stake in ARCADIA BIOSCIENCES, INC. |
| 01/06/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 01/05/2023 |
4
| Schaefer Thomas J. (CFO) has filed a Form 4 on Arcadia Biosciences, Inc.|
Txns:
| Granted 50,000 options to buy
@ $0.28, valued at
$14k
|
|
| 01/05/2023 |
3
| Schaefer Thomas J. (CFO) has filed a Form 3 on Arcadia Biosciences, Inc. |
| 01/05/2023 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/23/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 12/08/2022 |
8-K
| Quarterly results |
| 12/08/2022 |
8-A12G
| Form 8-A12G - Registration of securities [Section 12(g)]: |
|
|
|